Divi’s Laboratories Faces ₹570 Crore Tax Demand
On March 21,2026 company disclosed that it received a draft tax assessment order proposing additions of ₹570.51 crore to its income for FY 2022–23.
Tax Demand
Dr. Reddy’s Laboratories Receives GST Demand Orders Worth ₹2.20 Crore
Dr. Reddy’s Laboratories one of India’s leading pharmaceutical companies headquartered in Hyderabad, recently made headlines after disclosing GST demand orders totalling approximately ₹2.20 crore for the financial years FY20–22. Reported widely in March 2026, this development highlights the ongoing challenges companies face under India’s complex GST regime even those with strong compliance system.
Read MoreGland Pharma’s ₹6.29 Crore GST Dispute: What Investors Need to Know Introduction
Explore Gland Pharma’s ₹6.29 crore GST dispute from Telangana authorities over export reclassifications and credit notes for FY 2019-20. The company deems it unjustified and plans an appeal, assuring no major impact. Dive into company overview, market reactions, stock performance, and broader pharma sector implications as of March 9, 2026. Solid fundamentals persist amid short-term volatility.
Read More
